RecruitingPHASE1, PHASE2NCT05994534
PK and PD Study of NPI-001 and Cysteamine Bitartrate
Studying Cystinosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nacuity Pharmaceuticals, Inc.
- Principal Investigator
- Hugh McCarthy, PhD, FRACPSydney Children's Health Network
- Intervention
- Cysteamine Bitartrate(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 10 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Children's Hospital at Westmead, Westmead, New South Wales, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05994534 on ClinicalTrials.govOther trials for Cystinosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05508009Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same DonorAlice Bertaina
- ENROLLING BY INVITATIONNANCT05146830A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04Stephanie Cherqui
- RECRUITINGNANCT05959668Development of Health-related Quality of Life Instrument for Patients With CystinosisCystinose Stiftung
- RECRUITINGNANCT05843851Genetic Newborn Screening for Cystinosis and Primary HyperoxaluriaCystinose Stiftung
- ENROLLING BY INVITATIONNCT04246060Observational Study to Assess the Quality of Life in Nephropathic Cystinosis PatientsChiesi SA/NV
- RECRUITINGNCT05901077European Cystinosis CohortInstitut National de la Santé Et de la Recherche Médicale, France
- RECRUITINGNANCT00359684Use of Cysteamine in the Treatment of CystinosisNational Human Genome Research Institute (NHGRI)